Emricasan Disappoints for Severe Portal HTN in NASH

(MedPage Today) — Week 24 analysis of 48-week trial did not meet primary endpoint

Source link

Related posts

Early VTE linked with worse survival in pancreatic ductal adenocarcinoma


IQGAP1 promotes pancreatic cancer progression and epithelial-mesenchymal transition (EMT) through Wnt/β-catenin signaling


Exposure to maternal obesity during suckling outweighs in utero exposure in programming for post-weaning adiposity and insulin resistance in rats


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy